VivoSeq
Respiratory

Sleep Apnea

45

Pipeline Programs↗

10

Active Trials↗

24

Companies Involved↗

Sleep Apnea is a moderately active landscape with 45 programs across 24 companies. The most active players are Merck & Co., Retrophin, Shionogi Apnimed Sleep Science. 17 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

81/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1R

Retrophin

1 program

Phase 1S

Shionogi Apnimed Sleep Science

2 programs

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2M

Merz Pharmaceuticals GmbH

1 program

Phase 2M

Map77

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical3

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Sedative

Pontificia Universidad Catolica de Chile

Xylometazoline

Novartis

Phase 15

Oxytocin

Retrophin

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Modafinil

Nuvo Research GmbH

MK-7288

Merck & Co.

Cycloserine

University of Calgary

Phase 213

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Incobotulinumtoxina

Merz Pharmaceuticals GmbH

Medroxyprogesterone Acetate

Eli Lilly

Oxybutynin

Wim Janssens

Atomoxetine

Map77

Phase 37

Amlodipine

Viatris Specialty LLC

Diuretics

Boehringer Ingelheim

Metoprolol

Bp Consulting, Inc

Rozerem

Southern California Institute for Research and Education

Calcium Channel Blockers

Seoul National University Hospital

Approved17

Bexagliflozin

Theracosbio

Remifentanil

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Suvorexant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Losartan

Organon and Co

Pantoprazole

Wyeth-Lederle Vaccines

Analysis

Modality Breakdown

96%

Small molecule

49 of 51 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody12%Peptide12%

Small molecule leads; the ring shows all 51 classified programs, each share of the total. Modality classified for 98% of 53 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed25 · 50%
Unknown status9 · 18%
Recruiting8 · 16%
Terminated4 · 8%
Withdrawn2 · 4%
Enrolling by invitation2 · 4%

Clinical Trials

Trial Activity

50 trials

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
Recruiting·YYale University·Phase 4·NCT05612594·164 enrolled
Patient-centered and Neurocognitive Outcomes with Acetazolamide for Sleep Apnea
Recruiting·UUniversity of California, San Diego·Phase 2·NCT05804084·60 enrolled
Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment
Recruiting·VVA Office of Research and Development·Phase 4·NCT04118387·200 enrolled
Sleep Apnea in Elderly
Recruiting·VVA Office of Research and Development·Phase 4·NCT02703220·100 enrolled
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
Recruiting·UUniversity of California, San Diego·Phase 2·NCT05237505·240 enrolled
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
Recruiting·SShionogi Apnimed Sleep Science·Phase 2·NCT06776432·60 enrolled
Targeting Chemoreceptor Control of Breathing During Sleep to Mitigate Opioid-Associated Sleep Disordered Breathing
Recruiting·VVA Office of Research and Development·Preclinical·NCT05589753·150 enrolled
Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury
Recruiting·JJohn D. Dingell VA Medical Center·Approved·NCT02922894·100 enrolled
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve Positive Airway Pressure Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
Enrolling by invitation·UUniversity of Utah·Phase 2·NCT06649929·80 enrolled
The Importance of Dopamine and Selected Polymorphisms Within the Genes of the Dopaminergic Pathway in Assessment of the Risk of Development and Severity of Sleep Breathing Disorders.
Enrolling by invitation·WWroclaw Medical University·N/A·NCT05890911·100 enrolled
Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea
Completed·HHospital de Clinicas de Porto Alegre·Phase 4·NCT01945801·54 enrolled
Combination Therapy to Treat Sleep Apnea
Completed·—·N/A·NCT01633827·22 enrolled
Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI
Completed·VVA Office of Research and Development·Phase 2·NCT02458469·15 enrolled
Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01092780·56 enrolled
Managing Opioid Related Sleep Apnea With Acetazolamide
Completed·UUniversity of California, San Diego·Phase 2·NCT06043830·39 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)